Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cancer Immunology, Immunotherapy : CII|February 25, 2025
Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacyThierry Landre, Gaëtan Des Guetz
Soins. Gerontologie|September 18, 2017
[Checkpoint inhibitors, the perspectives for elderly patients]Thierry Landre, Fatima Karaoud, Cherifa Taleb
Journal of Chemotherapy (Florence, Italy)|February 2, 2024
Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC)Thierry Landre, Christos Chouaïd, Nassyma Sadaoui, et al.
Journal of Cancer Research and Clinical Oncology|November 6, 2019
First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancersThierry Landre, Gaetan Des Guetz, Kader Chouahnia, et al.
Soins. Gerontologie|February 16, 2013
[Assessment of nursing needs and risk management in geriatric oncology]Cherifa Taleb, Thierry Landre, Eric Bertrand, et al.
Therapeutic Advances in Medical Oncology|December 21, 2020
First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysisThierry Landre, Kader Chouahnia, Gaëtan Des Guetz, et al.
Pageof 2